Last reviewed · How we verify

NCT06311032

Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas

Completed Last updated 15 March 2024
What this trial tests

trial in Surgery Risk Assessment in 72 participants. Completed in 28 July 2023.

Timeline
29 March 2023
Primary endpoint
28 June 2023
28 July 2023

Quick facts

Lead sponsorNYU Langone Health
StatusCompleted
Study typeOBSERVATIONAL
Enrollment72
Start date29 March 2023
Primary completion28 June 2023
Estimated completion28 July 2023
Sites1 location across United States

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, any sex, with Surgery Risk Assessment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06311032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing